Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression

American Journal of Physiology - Endocrinology and Metabolism

Volumn 290, Issue 1, 2006, Pages

  Rasouli, Neda ^a,b   Yao Borengasser, Aiwei ^a   Miles, Leslie M ^a   Elbein, Steven C ^a   Kern, Philip A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Impaired glucose tolerance; Normal glucose tolerance; Thiazolidinedione

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN SENSITIZING AGENT; LEPTIN; MESSENGER RNA; METFORMIN; PIOGLITAZONE; RESISTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN, HUMAN; ANTIDIABETIC AGENT; INSULIN;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; ABDOMINAL FAT; BLOOD; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED;

ABDOMINAL FAT; ADIPONECTIN; ADULT; BLOOD GLUCOSE; FEMALE; GENE EXPRESSION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; METFORMIN; MIDDLE AGED; RESISTIN; THIAZOLIDINEDIONES;

EID: 33644875880     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00240.2005     Document Type: Article

References (37)

1. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, and Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45: 1684-1693, 1996.
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H,Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
3. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, and DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28: 783-789, 2004.
4. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, and DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89: 200-206, 2004.
5. Bergman RN, Ider YZ, Bowden CR, and Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab Gastrointest Physiol 236: E667-E677, 1979.
6. Bergman RN, Prager R, Volund A, and Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790-800, 1987.
7. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, and Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
8. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, and Despres JP. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90: 1434-1439, 2005.
9. Fullert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, Usadel KH, and Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 87: 5503-5506, 2002.
10. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, and Nuutila P. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51: 3479-3485, 2002.
11. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
12. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, and Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663, 2003.
13. Kadowaki T and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451, 2005.
14. Kern PA, Di Gregorio GB, Lu T, Rassouli N, and Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52: 1779-1785, 2003.
15. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, and Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219: 9-15, 2004.
16. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, and Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58, 2002.
17. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
18. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, and DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784-2791, 2002.
19. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, and DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89: 4312-4319, 2004.
20. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, and Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87: 5662-5667, 2002.
21. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, and Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085, 2003.
22. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, and Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162, 2004.
23. Petersen KF, Dufour S, Befroy D, Garcia R, and Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664-671, 2004.
24. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, and Henry RR. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52: 667-674, 2003.
25. Ross R, Shaw KD, Martel Y, de Guise J, and Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr 57: 470-475, 1993.
26. Sato C, Yasukawa Z, Honda N, Matsuda T, and Kitajima K. Identification and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, Adipo Q. J Biol Chem 276: 28849-28856, 2001.
27. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749, 1995.
28. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, and Lazar MA. The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001.
29. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169-2176, 2004.
30. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF, and Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99: 16309-16313, 2002.
31. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, and Hawkins M. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53: 1621-1629, 2004.
32. Trujillo ME and Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257: 167-175, 2005.
33. Ukkola O and Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80: 696-702, 2002.
34. Wang Y, Xu A, Knight C, Xu LY, and Cooper GJS. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. J Biol Chem 277: 19521-19529, 2002.
35. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
36. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, and Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25: 376-380, 2002.
37. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, and Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968-2974, 2002.